Skip to main content
main-content

Sodium-glucose cotransporter 2 (SGLT2) inhibitors

medwireNews editor's pick

No fracture risk found with canagliflozin in real-world data

Cervical hip (femoral neck) fracture

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

medwireNews editor's pick

Older type 2 diabetes patients may derive greatest liraglutide benefits

Elderly diabetic patient (symbolic image with models)

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

Pills

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

Case study

Acute illness while on a SGLT2 inhibitor and ketogenic diet

AdobeStock_88855376

Advisory Board member Theresa Smyth tackles an emergency case involving a type 2 diabetes patient on a new diet and treated with empagliflozin. What went wrong and how should he be managed? [Read more].

Get more on: SGLT2 inhibitors | Diet and nutritional management | Case studies

medwireNews editor's pick

Research adds to SGLT2 inhibitor amputation risk debate

Pills_two types

Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.

medwireNews editor's pick

No significant increase in amputation risk with SGLT2 inhibitors in real-world study

Pills

Patients with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors have numerically higher rates of amputation than those given dipeptidyl peptidase-4 inhibitors, but the difference does not reach statistical significance, researchers report.

Journal article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Nurse measuring blood pressure (symbolic image with models)

This review presents the evidence from old and recent trials relevant to optimal blood pressure levels in diabetes mellitus, aiming to shed light in this major clinical question [read more].
Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

Get more on:  Diabetic complications | Type 2 diabetes

Journal article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Woman measuring her waist (symbolic image with model)

This post hoc analysis investigated the metabolic effects and baseline associations with bodyweight loss on coadministration of dapagliflozin and exenatide once weekly among adults with obesity and without diabetes [read more].
Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

Get more on:  Medication | Obesity | Type 2 diabetes

medwireNews

01-08-2019 | Dapagliflozin | News

Observational data hint at additional dapagliflozin benefits

A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits